Tatiana Shaurova

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR-Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance”.

Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR-Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance

Cancers(2020)10.3390/cancers12030675

N/A

0DataRank · unranked

20 citations

Grace K. Dy, Sebastiano Battaglia, Alan D. Hutson, Letian Zhang, Yunkai Zhang +6 more

Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)

ChemRxiv(2022)10.26434/chemrxiv-2022-5m8h5-v2

N/A

0DataRank · unranked

3 citations

Tyler S. Beyett, Tatiana Shaurova, Calvin Pham, Florian Wittlinger, Ilse K. Schaeffner +6 more

Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)

ChemRxiv(2022)10.26434/chemrxiv-2022-5m8h5

N/A

0DataRank · unranked

0 citations

Tyler S. Beyett, Tatiana Shaurova, Calvin Pham, Florian Wittlinger, Ilse K. Schaeffner +6 more

A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer

Cancer Communications(2023)10.1002/cac2.12401

N/A

0DataRank · unranked

6 citations

Lingyue Yan, Yafei Su, Laurie J. Rich, Vui King Vincent–Chong, Hannah Calkins +6 more

Examining molecular factors of inactive versus active bivalent EGFR inhibitors: A missing link in fragment-based drug design.

ChemRxiv(2023)10.26434/chemrxiv-2023-cs3xn

N/A

0DataRank · unranked

3 citations

Blessing C. Ogboo, Calvin D. Pham, Ilse K. Schaeffner, Surbhi P. Chitnis, Tahereh Damghani +12 more

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors

ChemRxiv(2023)10.26434/chemrxiv-2023-cs3xn-v2

N/A

0DataRank · unranked

3 citations

Blessing C. Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin D. Pham, Ilse K. Schaeffner +15 more

The origin of potency and mutant-selective inhibition by bivalent ATP-allosteric EGFR inhibitors

ChemRxiv(2023)10.26434/chemrxiv-2023-zzfc3

N/A

0DataRank · unranked

2 citations

Surbhi P. Chitnis, Calvin D Pham, Tahereh Damghani, Ilse K. Schaeffner, Matthew Q. Deng +13 more

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors

Research Square(2023)10.21203/rs.3.rs-3286949/v1

N/A

0DataRank · unranked

0 citations

Florian Wittlinger, Blessing C. Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin Pham +15 more

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors

Communications Chemistry(2024)10.1038/s42004-024-01108-3

N/A

0DataRank · unranked

24 citations

Blessing C. Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin D. Pham, Ilse K. Schaeffner +15 more

Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent “Type V” Kinase Inhibitors

Journal of Medicinal Chemistry(2024)10.1021/acs.jmedchem.4c02311

N/A

0DataRank · unranked

8 citations

Surbhi P. Chitnis, Calvin D. Pham, Tahereh Damghani, Kishan B. Patel, Mareike Möllers +17 more